Integration of onchocerciasis morbidity management and disability prevention services in the healthcare system in Tanzania: a call for action and recommendations.
Epilepsy
Ivermectin and Tanzania
Morbidity Management and Disability Prevention
Onchocerciasis
Journal
Tropical diseases, travel medicine and vaccines
ISSN: 2055-0936
Titre abrégé: Trop Dis Travel Med Vaccines
Pays: England
ID NLM: 101674442
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
30
10
2023
accepted:
16
11
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Onchocerciasis is among the Neglected Tropical Diseases (NTDs) responsible for dermatological, ophthalmological, and neurological manifestations. With the ongoing burden of onchocerciasis clinical manifestations, morbidity management, and disability prevention services are required to alleviate the suffering of the affected populations. Unfortunately, despite the ongoing transmission of onchocerciasis, morbidity management, and disability prevention services are limited in Tanzania. Therefore, this article highlights the concept of onchocerciasis morbidity management and disability prevention, along with the significance of its adoption in the healthcare system in Tanzania. We further provide recommendations on where and how to start.
Identifiants
pubmed: 38167350
doi: 10.1186/s40794-023-00211-y
pii: 10.1186/s40794-023-00211-y
doi:
Types de publication
Letter
Langues
eng
Pagination
1Informations de copyright
© 2023. The Author(s).
Références
Neglected Tropical Diseases Control Programme. Global Onchocerciasis Network for Elimination (GONE) Webinar -Tanzania Oncho Elimination Updates. 2022.
Gyasi ME, Okonkwo ON, Tripathy K, Onchocerciasis. Ecol Heal Dis Ethiop. 2022;367–74. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559027/ .
Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme J. Onchocerciasis: the clinical and epidemiological burden of Skin Disease in Africa. Ann Trop Med Parasitol. 2002;96(3):283–96. https://doi.org/10.1179/000349802125000826 .
doi: 10.1179/000349802125000826
pubmed: 12061975
Neglected Tropical Diseases Control Program. 5th Annual Joint Planning Meeting. Ministry of Health, Community, Development, Gender, Elderly and Children. 2016.
Mushi V. Factors associated with persistence of onchocerciasis transmission after two decades of Community Directed Treatment with Ivermectin in Ulanga District Council. Masters Thesis. 2018.
Mwaiko GL, Mtoi RS, Mkufya AR. Onchocerciasis prevalence in Tanzania. Cent Afr J Med. 1990;36(4):94–6.
pubmed: 2225028
Neglected Tropial Diseases Control Programme. 6th Annual Joint Planning Meeting. Ministry of Health, Community, Development, Gender, Elderly and Children. 2017. 21 p.
Colebunders R, Basáñez M-G, Siling K, Post RJ, Rotsaert A, Mmbando B et al. From river blindness.
Mweya CN, Kalinga AK, Kabula B, Malley KD, Ruhiso MH, Maegga BT. Onchocerciasis situation in the Tukuyu focus of southwest Tanzania after ten years of ivermectin mass treatment. Tanzan Health Res Bull. 2007;174–9. https://doi.org/10.4314/thrb.v9i3.14325 .
Kalinga AK, Mweya CN, Barro T, Maegga BT. Susceptibility of Simulium Damnosum complex larvae to temephos in the Tukuyu onchocerciasis focus, southwest Tanzania. Tanzan Health Res Bull. 2007;9(1):19–24. https://doi.org/10.4314/thrb.v9i1.14287 .
doi: 10.4314/thrb.v9i1.14287
pubmed: 17547096
Mmbando BP, Suykerbuyk P, Mnacho M, Kakorozya A, Matuja W, Hendy A, et al. High prevalence of Epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community-directed treatment with ivermectin. Infect Dis Poverty. 2018;7(1):64. https://doi.org/10.1186/s40249-018-0450-3 .
doi: 10.1186/s40249-018-0450-3
pubmed: 29921319
pmcid: 6009039
Mshana MI, Silvestri V, Mushi V, Bonaventura WM, Tarimo D, Ngasala B, et al. Burden and factors associated with onchocerciasis transmission among school-aged children after more than 20 years of Community Directed Treatment with Ivermectin in Ulanga district, Tanzania: a school-based cross-sectional study. PLOS Glob Public Health. 2023;3(5):e0001919. https://doi.org/10.1371/journal.pgph.0001919 .
doi: 10.1371/journal.pgph.0001919
pubmed: 37172010
pmcid: 10180657
Mushi V. Implementation challenges of Community Directed Treatment with Ivermectin Program for Control of Onchocerciasis in Ulanga, Tanzania. East Afr Health Res J. 2021;5(2):123–8. https://doi.org/10.24248/eahrj.v5i2.661 . Epub 2021 Nov 15.
doi: 10.24248/eahrj.v5i2.661
pubmed: 35036836
pmcid: 8751475
York KJ, Kabole I, Mrisho M, Berry DM, Schmidt E. Factors affecting community participation in the CDTI program in Morogoro, Tanzania. J Nurs Scholarsh. 2015;47(1):96–104. https://doi.org/10.1111/jnu.12121 .
doi: 10.1111/jnu.12121
pubmed: 25565278
Mushi V, Kakoko D, Tarimo D, Knowledge. Attitudes, perceptions and acceptability of Onchocerciasis Control through Community-Directed treatment with ivermectin: implications for persistent transmission in Ulanga district, Tanzania. E Afr J Appl Health Monitoring and Eval. 2020;4:28–35.
Bhwana D, Amaral L-J, Mhina A, Matine P, Francis F, Siewe Fodjo JN, et al. Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of Epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: a population-based prospective study. PLoS Negl Trop Dis. 2023;17(6):e0011178.
doi: 10.1371/journal.pntd.0011178
pubmed: 37379350
pmcid: 10335697
Jada SR, Carter JY, Rovarini J, Claver P, Ojok M, Lakwo T et al. Tackling onchocerciasis-associated epilepsy New evidence and recommendations for policymakers. Available from: https://www.elrha.org/researchdatabase/tackling-onchocerciasis-associated-epilepsy-new-evidence-and-recommendations-for-policymakers/ (accessed 5 August 2023).
Vinkeles Melchers NVS, Mollenkopf S, Colebunders R, Edlinger M, Coffeng LE, Irani J et al. Burden of onchocerciasis-associated epilepsy: First estimates and research priorities. Infect Dis Poverty. 2018;7(1):1–12. Available from: https://idpjournal.biomedcentral.com/articles/ https://doi.org/10.1186/s40249-018-0481-9 .
Levick B, Laudisoit A, Tepage F, Ensoy-Musoro C, Mandro M, Bonareri Osoro C, et al. High prevalence of Epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2017;11(7):e0005732. https://doi.org/10.1371/journal.pntd.0005732 .
doi: 10.1371/journal.pntd.0005732
pubmed: 28708828
pmcid: 5529017
Colebunders R, Carter Y, Olore J, Puok PC, Bhattacharyya K, Menon S. High prevalence of onchocerciasis-associated Epilepsy in villages in Maridi County, Republic of South Sudan: a community-based survey. Seizure. 2018;63:93–101.
doi: 10.1016/j.seizure.2018.11.004
pubmed: 30468964
pmcid: 6291739
Jada SR, Dusabimana A, Abd-Elfarag G, Okaro S, Brusselaers N, Carter JY, et al. The prevalence of Onchocerciasis-Associated Epilepsy in Mundri West and East Counties, South Sudan: a door-to-Door Survey. Volume 11. Pathog; 2022. (Basel, Switzerland). 4.
Raimon S, Dusabimana A, Abd-Elfarag G, Okaro S, Carter JY, Newton CR, et al. High prevalence of Epilepsy in an onchocerciasis-endemic area in Mvolo County, South Sudan: a Door-To-Door survey. Pathogens. 2021;10(5):599. https://doi.org/10.3390/pathogens10050599 .
doi: 10.3390/pathogens10050599
pubmed: 34068976
pmcid: 8157079
Gumisiriza N, Mubiru F, Siewe Fodjo JN, Mbonye Kayitale M, Hotterbeekx A, Idro R et al. Prevalence and incidence of nodding syndrome and other forms of Epilepsy in onchocerciasis-endemic areas in northern Uganda after the implementation of onchocerciasis control measures. Infect Dis Poverty. 2020;9(1).
Siewe JFN, Ngarka L, Tatah G, Mengnjo MK, Nfor LN, Chokote ES et al. Clinical presentations of onchocerciasis-associated Epilepsy (OAE) in Cameroon. Epilepsy Behav. 2019;90.
Mukendi D, Tepage F, Akonda I, Siewe JNF, Rotsaert A, Ndibmun CN et al. High prevalence of Epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: a mixed-method assessment. Int J Infect Dis. 2019;79.
Siewe Fodjo JN, Tatah G, Tabah EN, Ngarka L, Nfor LN, Chokote SE et al. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: Impact of more than 13 years of ivermectin. Infect Dis Poverty. 2018;7(1):1–11. Available from: https://idpjournal.biomedcentral.com/articles/ https://doi.org/10.1186/s40249-018-0497-1 .
Van Cutsem G, Siewe Fodjo JN, Dekker MCJ, Amaral LJ, Njamnshi AK, Colebunders R. Case definitions for onchocerciasis-associated epilepsy and nodding syndrome: A focused review. Seizure. 2023;107:132–5. Available from: https://pubmed.ncbi.nlm.nih.gov/37023626/ .
Colebunders R, Abd-Elfarag G, Carter JY, Olore PC, Puok K, Menon S et al. Clinical characteristics of onchocerciasis-associated Epilepsy in villages in Maridi County, Republic of South Sudan. Seizure. 2018;62.
World Health Organization. Morbidity management and disability prevention (MMDP). Available from: https://www.who.int/activities/building-capacity-of-national-programmes-to-implement-who-recommended-strategies/morbidity-management-and-disability-prevention (Accessed 1 August 2023).
Vinkeles Melchers NVS, Stolk WA, van Loon W, Pedrique B, Bakker R, Murdoch ME, et al. The burden of Skin Disease and eye Disease due to onchocerciasis in countries formerly under the African programme for onchocerciasis control mandate for 1990, 2020, and 2030. PLoS Negl Trop Dis. 2021;15(7):1–18.
doi: 10.1371/journal.pntd.0009604
World Health Organization. Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030. 2020;(5):6–9.
Crump A, Ōmura S, Ivermectin. Wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13–28. https://doi.org/10.2183/pjab.87.13 .
doi: 10.2183/pjab.87.13
pubmed: 21321478
pmcid: 3043740
Dusabimana A, Bhwana D, Raimon S, Mmbando BP, Hotterbeekx A, Tepage F, et al. Ivermectin Treatment Response in Onchocerca Volvulus Infected Persons with Epilepsy: A Three-Country Short Cohort Study. Pathogens. 2020;9(8):617. https://doi.org/10.3390/pathogens9080617 .
doi: 10.3390/pathogens9080617
pubmed: 32751060
pmcid: 7460326
Bush S, Richards FO, Zhang Y. The role of non-governmental development organizations in the implementation of lymphatic filariasis programmes. Int Health. 2020;13(Suppl 1):44–S47. https://doi.org/10.1093/inthealth/ihaa049 .
doi: 10.1093/inthealth/ihaa049
Hellen Keller International. MMDP Project Resources. Available from: https://helenkellerintl.org/what-we-do/knowledge-resources/neglected-tropical-diseases/mmdp-project-resources/ (Accessed 12 November 2023).
Bhwana D, Mmbando BP, Dekker MC, Mnacho M, Kakorozya A, Matuja W, et al. Clinical presentation of Epilepsy in six villages in an onchocerciasis endemic 32area in Mahenge, Tanzania. Epileptic Disord. 2019;21(5):425–35.
pubmed: 31649005
Stelzle D, Makasi C, Schmidt V, Trevisan C, van Damme I, Welte TM. Epidemiological, clinical and radiological characteristics of people with neurocysticercosis in Tanzania-A cross-sectional study. PLoS Negl Trop Dis. 2022;16(11):e0010911. https://doi.org/10.1371/journal.pntd.0010911 .
doi: 10.1371/journal.pntd.0010911
pubmed: 36441777
pmcid: 9704569
Hunter E, Burton K, Iqbal A, Birchall D, Jackson M, Rogathe J, et al. Cysticercosis and Epilepsy in rural Tanzania: a community-based case-control and imaging study. Trop Med Int Health. 2015;20(9):1171–9. https://doi.org/10.1111/tmi.12529 .
doi: 10.1111/tmi.12529
pubmed: 25940786
pmcid: 5496663
Bhwana D, Massawe IS, Mushi AK, Magili P, Amaral L-J, Makunde W, et al. Factors associated with low-uptake of ivermectin in Mahenge, an area with high prevalence of onchocerciasis and Epilepsy in Tanzania: a qualitative perspective. Front Trop Dis. 2023;4:1–10.
doi: 10.3389/fitd.2023.1079012